Navigation Links
Niusule Biotech Corp. Formally Establishes a New Venture to Import and Sell Health Foods in the People's Republic of China
Date:3/10/2009

HANGZHOU, China and CARSON CITY, Nev., March 10 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. (OTC Bulletin Board: NIUS) announces that its new Venture, Niusule Bioengineering (Hangzhou) Co., Ltd., has been formally established by obtaining the "Certificate of Approval for Establishment of Enterprises with Foreign Investment in the People's Republic of China" from Zhejiang Foreign Trade & Economic Cooperation Bureau on March 2, 2009 and the Business License from Hangzhou Industrial and Commerce on March 4, 2009.

The development of the Venture will continue by:

  • Submitting the application to Hangzhou Administration of Foreign Exchange for the Foreign Exchange Registration Certificate of Foreign-funded Enterprise of Niusule Bioengineering (Hangzhou) Co., Ltd. in March 2009.
  • Submitting the application to Zhejiang Food and Drug Administration for the approval of health food used in Zhejiang Province in April 2009.

Niusule Biotech Corp. will continue the development of its business plan by:

  • Signing production agreements with certain U.S. health food manufacturers in March 2009. We are currently assessing suppliers, products and quantities.
  • Executing the distribution agreement with Niusule Bioengineering (Hangzhou) Co., Ltd. in late March 2009, which we need to do in order to import and sell our products in China.

When Niusule Bioengineering (Hangzhou) Co., Ltd. is established and approved by government regulatory authorities, we plan to open 10 Niusule Health Food Stations in Zhejiang province to sell health food products, focusing on products imported from the U.S.

"This new venture signals our commitment to being a leading player in China's health food industry," said Chairman Mrs. Qinghua Hu of Niusule Biotech Corp. "We believe that China has witnessed significant economic growth during recent years and that more people have attained the means and desire to have a healthy lifestyle. We are confident in our bright future and welcome qualified companies to cooperate with us."

About Niusule Biotech Corp.

Niusule Biotech Corp, through its wholly-owned subsidiary, Niusule Bioengineering (Hangzhou) Co., Ltd., plans to sell in China, various health food and related products some of which it intends to import from the U.S.

Safe Harbor Statement

The statements contained herein that are not historical facts are 'forward-looking statements' within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as 'believes,' 'expects,' 'may,' 'will,' 'should,' or 'anticipates,' 'expect' or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets or forecasting financial results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward-looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


'/>"/>
SOURCE Niusule Biotech Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Niusule Biotech Corp. to Commence Trading on the OTC Bulletin Board Under the Symbol NIUS
2. Pharma ChemOutsourcing Unveils 100 Pharma & Biotech Speaker Faculty for 2009 Conference September 14-16 in Long Branch, NJ
3. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
4. Canadian Government Announces Funding for Leading Biotechnology Firms Project
5. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
6. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
7. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
8. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
9. Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener
10. Morningstar Healthcare Analysts to Discuss Top 15 Biotech Acquisition Targets on Wednesday, March 4 at 11 a.m. EST
11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):